RedShift BioAnalytics Inc. (RedShiftBioR), a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, announced today the closing of its Series E Preferred Stock financing. The $20 million financing was led by Illumina Ventures and joined by all of the company’s current major investors, including Technology Venture Partners and Waters Corporation. Proceeds of the financing will be used to fund additional commercial expansion, continued technology innovation, and execution of its product development objectives.